Your landing page’s weakest score is Trust.
How LionBio Therapeutics ranks
- 1.
LionBio Therapeutics75
- 2.
Rani Therapeutics74
- 3.
Entera Bio61
- 4.
Structure Therapeutics53
- 5.
Oramed Pharmaceuticals48
75Growth scoreupdated
category scores
category scoresShowHide
Lazyweb TeamAI Growth PMTurn this score into growth.Analyze your site and propose fixes across conversion and trustBenchmark your Growth Score against similar companiesLearn from growth experiments across 10,000+ top productsStart Team trial →Score over time
Trust
64FairProof that the product is real, competent, and safe to try.
| Trust read | |
|---|---|
| LionBio Therapeutics | "Columbia — University spinout technology" credential in the stats strip |
| "3 Phase 1 studies completed" stat badge | |
| No visible trust signal identified. | |
| No visible trust signal identified. | |
| No visible trust signal identified. |
Information hierarchy
73FairDoes the design help or inhibit what the page is trying to say?
123- Explore our research — Dark green on black hero gives the primary CTA the lowest contrast of any button on the page.
- View open roles — White secondary button outshines the primary CTA at equal size, splitting the click between two actions.
- Careers nav pill — Reuses the primary CTA's green fill, pulling first-glance attention to the top-right exit.
CTA
76FairCopy, size, verb, cost-feel — does the primary CTA earn the click?
Problems
- 'Explore' is a soft, vague verb
- no header echo of GLP-1 hook
- payoff of the click is unclear
Mobile web
78FairThe phone experience as a first-class citizen.
1234- Top nav link row — Desktop pill links (Team/Research/Blog/Careers) are crammed in uncollapsed instead of a hamburger menu.
- Explore our research button — Primary CTA floats at roughly half the column width instead of a full-bleed, thumb-friendly bar.
- Hero headline — Serif headline scales up too far, wrapping into four lines and eating a quarter of the fold.
- View open roles button — Secondary CTA is styled at near-equal weight and stacks directly under the primary, splitting the tap decision.
Value props
82StrongTitle, subtitle, hero — do they sell the product's true value?
LionBio Therapeutics’s headline sells
The world's first GLP-1s taken through your nose.
Direct-to-brain and less nausea. Next gen intranasal peptide therapeutics powered by our precision nanoparticle technology.
Working
- World-first claim is concrete and instantly parseable
- 'Less nausea' targets the category's real pain point
- 30+ years IP and Columbia spinout add credibility
Could improve
- 'Less nausea' has no supporting number
- Hero render decorates, doesn't show mechanism
- No development stage or trial status shown